Non-alcoholic fatty liver disease (NAFLD) is a hepatic metabolic syndrome resulting from lipid metabolic imbalance.

What's been exciting over the last 5-10 years has been the growing body of evidence with interferon alpha therapy for these diseases that really looks like it has an impact on preventing the ...

Whilst recombinant and natural interferons are among the most common biological therapeutics worldwide, interferon inducers are hardly mentioned in the West. With the increase in antibiotic ...

A drug and alcohol charity in Leeds has said it has "micro-eliminated" hepatitis C - meaning it has identified, treated and ...

IRF8, interferon regulatory factor 8; NAFLD, non-alcoholic fatty liver disease; HFD, high-fat diet; CD, chow diet. Non-alcoholic fatty liver disease (NAFLD) is a hepatic metabolic syndrome ...

High serum type I interferon (IFN) scores, measured through six chemokines, correlated with poorer lung function and health-related quality of life in patients with diffuse cutaneous systemic ...

The patient was on maintenance dialysis and was receiving pegylated interferon monotherapy for her chronic hepatitis C virus infection. Investigations. Physical examination, laboratory tests ...

EULAR - The European Alliance of Associations for Rheumatology - held its 2024 congress in Vienna, where new work was unveiled on the potential value of the blood interferon signature in pediatric ...

Motzer and colleagues present updated results from a multicenter, phase III trial of sunitinib versus interferon-α as first-line treatment for patients with metastatic renal-cell carcinoma.

Valnei Canutti, Hematologist and Chief Scientific Officer at Pint Pharma, emphasized that "BESREMi® is an innovative, monopegylated interferon with extended action due to its unique ...

Non-alcoholic fatty liver disease (NAFLD) is a hepatic metabolic syndrome resulting from lipid metabolic imbalance.